Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on April 24, 2023. The filing addresses a notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and listing status.
Material Changes and Listing Status
On April 24, 2023, the Company received a Nasdaq Staff Deficiency Letter stating that its common stock closing bid price had been below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The Company has been granted an initial 180-day compliance period, ending October 23, 2023, to regain compliance. Compliance can be achieved if the closing bid price remains at or above $1.00 for ten consecutive business days during this period.
Outlook, Risks, and Management Commentary
- Compliance Options: If the Company fails to regain compliance by October 23, 2023, it may be eligible for an additional 180-day period. This would require transferring to The Nasdaq Capital Market and meeting its initial listing standards (excluding the bid price requirement).
- Reverse Stock Split: To cure the deficiency during a potential second compliance period, the Company may need to effect a reverse stock split, subject to shareholder approval and Nasdaq approval.
- Delisting Risk: There is no assurance that the Company will regain compliance or be granted additional time. Failure to cure the deficiency could result in delisting.
- Management Intent: The Company intends to actively monitor the bid price and consider available actions to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of DTIL stock to assess proximity to the $1.00 threshold.
- Monitor upcoming announcements regarding the potential implementation of a reverse stock split.
- Review the Company's most recent Form 10-K for detailed financial health and liquidity status, as this 8-K does not provide such data.
- Track the October 23, 2023 deadline for the initial compliance period.